| Symbol | TCRX |
|---|---|
| Name | TSCAN THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 830 WINTER STREET, WALTHAM, Massachusetts, 02451, United States |
| Telephone | +1 857 399-9500 |
| Fax | — |
| — | |
| Website | https://www.tscan.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001783328 |
| Description | TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The companys lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - TScan Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000902664-26-003526 <b>Size:</b> 10 KB
Read more(30% Negative) TSCAN THERAPEUTICS, INC. (TCRX) Reports Q3 2026 Financial Results
Read moreTScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Read moreTScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Read moreTScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
Read moreCellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
Read moreBAKER BROS. ADVISORS LP 🟢 acquired 134.0K shares (2 derivative) of TScan Therapeutics, Inc. (TCRX) at $0.99 Transaction Date: May 20, 2026 | Filing ID: 236870
Read more(99% Neutral) TSCAN THERAPEUTICS, INC. (TCRX) Announces Regulatory Update
Read moreWoods Keith 🟢 acquired 67.0K shares (1 derivative) of TScan Therapeutics, Inc. (TCRX) at $0.99 Transaction Date: May 20, 2026 | Filing ID: 236855
Read moreGruia Gabriela 🟢 acquired 67.0K shares (1 derivative) of TScan Therapeutics, Inc. (TCRX) at $0.99 Transaction Date: May 20, 2026 | Filing ID: 236848
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07702578 | A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allo… | Phase3 | AML | Recruiting | 2026-06-18 | 2029-06-01 | ClinicalTrials.gov |
| NCT06976736 | A Long Term Follow-up Study of TScan TCR-T Products | — | AML | Recruiting | 2025-09-09 | 2040-09-01 | ClinicalTrials.gov |
| NCT05973487 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With L… | Phase1 | Head and Neck Cancer | Active_Not_Recruiting | 2024-05-06 | 2026-12-30 | ClinicalTrials.gov |
| NCT05812027 | A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity … | — | Head and Neck Cancer | Active_Not_Recruiting | 2023-06-26 | 2027-01-14 | ClinicalTrials.gov |
| NCT06587828 | A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Ce… | — | Autoimmune Diseases | Recruiting | 2023-01-03 | 2027-01-01 | ClinicalTrials.gov |
| NCT05473910 | A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Under… | Phase1 | AML | Recruiting | 2022-11-01 | 2028-06-01 | ClinicalTrials.gov |
| NCT05230186 | A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibito… | — | Solid Tumor, Adult | Unknown | 2021-02-26 | 2024-12-23 | ClinicalTrials.gov |
| NCT04680416 | Tissue Collection to ID TCRs From Renal Clear Cell Carcinoma Patients Respondin… | — | Renal Clear Cell Carcinoma | Withdrawn | 2020-12-17 | 2021-08-04 | ClinicalTrials.gov |
| NCT04397900 | Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to I… | — | Identify the Viral Epitopes of Memory CD8 T Cells From Individuals That Have Recovered From SARS-CoV-2 Infection | Completed | 2020-04-09 | 2021-04-12 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Control | Other | Phase PHASE3 | AML | RECRUITING | NCT07702578 |
| TSC-101 | Other | Phase PHASE3 | AML | RECRUITING | NCT07702578 |
| SOC + TSC-100 | Other | Phase PHASE1 | AML | RECRUITING | NCT05473910 |
| Control | Other | Phase PHASE1 | AML | RECRUITING | NCT05473910 |
| SOC + TSC-101 | Other | Phase PHASE1 | AML | RECRUITING | NCT05473910 |
| SOC + TSC-100 | Other | Phase PHASE1 | AML | RECRUITING | NCT05473910 |
| Control | Other | Phase PHASE1 | AML | RECRUITING | NCT05473910 |
| SOC + TSC-101 | Other | Phase PHASE1 | AML | RECRUITING | NCT05473910 |
| Control | Other | Phase PHASE3 | AML | RECRUITING | NCT07702578 |
| TSC-101 | Other | Phase PHASE3 | AML | RECRUITING | NCT07702578 |
| Observational | Other | Preclinical | AML | RECRUITING | NCT06976736 |
| Tumor Biopsy | Other | Preclinical | Solid Tumor, Adult | UNKNOWN | NCT05230186 |
| TSC-201-B0702 + TSC-202-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0101 + TSC-202-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-203-A0201 + TSC-202-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-200-A0201 + TSC-202-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-C0702 + TSC-202-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 + TSC-202-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-202-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-203-A0201 + TSC-201-B0702 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-203-A0201 + TSC-204-A0101 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-200-A0201 + TSC-201-B0702 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-200-A0201 + TSC-204-A0101 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-C0702 + TSC-201-B0702 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-C0702 + TSC-204-A0101 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 + TSC-201-B0702 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 + TSC-204-A0101 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-201-B0702 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0101 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-203-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-200-A0201 + TSC-203-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-C0702 + TSC-203-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 + TSC-203-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-C0702 + TSC-200-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 + TSC-200-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 + TSC-204-C0702 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-200-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-C0702 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| Tumor and HLA Profiling | Other | Preclinical | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05812027 |
| Companion blood samples with procedure | Procedure | Preclinical | Autoimmune Diseases | RECRUITING | NCT06587828 |
| Control | Other | Phase PHASE1 | AML | RECRUITING | NCT05473910 |
| SOC + TSC-101 | Other | Phase PHASE1 | AML | RECRUITING | NCT05473910 |
| SOC + TSC-100 | Other | Phase PHASE1 | AML | RECRUITING | NCT05473910 |
| Observational | OTHER | Preclinical | AML | RECRUITING | NCT06976736 |
| Companion blood samples with procedure | PROCEDURE | Preclinical | Autoimmune Diseases | RECRUITING | NCT06587828 |
| TSC-201-B0702 + TSC-202-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0101 + TSC-202-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-203-A0201 + TSC-202-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-200-A0201 + TSC-202-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-C0702 + TSC-202-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 + TSC-202-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-202-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-203-A0201 + TSC-201-B0702 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-203-A0201 + TSC-204-A0101 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-200-A0201 + TSC-201-B0702 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-200-A0201 + TSC-204-A0101 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-C0702 + TSC-201-B0702 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-C0702 + TSC-204-A0101 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 + TSC-201-B0702 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 + TSC-204-A0101 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-201-B0702 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0101 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-203-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-200-A0201 + TSC-203-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-C0702 + TSC-203-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 + TSC-203-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-C0702 + TSC-200-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 + TSC-200-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 + TSC-204-C0702 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-200-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-C0702 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| Control | OTHER | Phase PHASE1 | AML | RECRUITING | NCT05473910 |
| SOC + TSC-101 | DRUG | Phase PHASE1 | AML | RECRUITING | NCT05473910 |
| SOC + TSC-100 | DRUG | Phase PHASE1 | AML | RECRUITING | NCT05473910 |
| Tumor Biopsy | PROCEDURE | Preclinical | Solid Tumor, Adult | UNKNOWN | NCT05230186 |